SALT LAKE CITY, UT--(Marketwire - March 23, 2009) - Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at Citi's 4th Annual Biotech Day, at 3:20 p.m. on April 1, at the 338 Greenwich Street Conference Center in New York, NY.
About Myriad Genetics
Myriad Genetics, Inc. is a leading healthcare company focused on the development and marketing of novel molecular diagnostic and therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, Azixa and Vivecon are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G
This press release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements relating to the scheduled presentation of an overview of the
Company at Citi's 4th Annual Biotech Day on April 1, 2009. These
forward-looking statements are based on management's current expectations
of future events and are subject to a number of risks and uncertainties
that could cause actual results to differ materially and adversely from
those set forth in or implied by forward-looking statements. These risks
and uncertainties include, but are not limited to: the risk that we may be
unable to further identify, develop and achieve commercial success for new
products and technologies; the risk that we may be unable to discover drugs
that are safer and more efficacious than our competitors; the risk that we
may be unable to develop manufacturing capability for approved products;
the risk that sales of our existing molecular diagnostic products may
decline or not continue to increase at historical rates; the risk that we
may be unable to develop additional molecular diagnostic products that help
assess which patients are subject to greater risk of developing diseases
and who would therefore benefit from new preventive therapies; the
possibility of delays in the research and development necessary to select
drug development candidates and delays in clinical trials; the risk that
clinical trials may not result in marketable products; the risk that we may
be unable to successfully finance and secure regulatory approval of and
market our drug candidates, or that clinical trials will not be completed
on the timelines we have estimated; uncertainties about our ability to
obtain new corporate collaborations and acquire new technologies on
satisfactory terms, if at all; the development of competing products and
services; the risk that we may be unable to protect our proprietary
technologies; the risk of patent-infringement claims; risks of new,
changing and competitive technologies and regulations in the United States
and internationally; and other factors discussed under the heading "Risk
Factors" contained in Item 1A in our Annual Report on Form 10-K for the
year ended June 30, 2008, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors filed
from time to time in our Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K. All information in this press release is as of the date of the
release, and Myriad undertakes no duty to update this information unless
required by law.
